共 50 条
- [1] Efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor TAK-279 in two preclinical mouse models of colitisJOURNAL OF CROHNS & COLITIS, 2024, 18 : I437 - I438Kong, K. F.Khan, M. A. W.Singh, N.Nguyen, V. A.Wilson, E.Tang, J.Marusic, S.Xia, G.Petrakis, I.Nguyen, D. G.
- [2] Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (15) : 10473 - 10496Leit, SilvanaGreenwood, JeremyCarriero, SamanthaMondal, SayanAbel, RobertAshwell, MarkBlanchette, HeatherBoyles, Nicholas A. A.Cartwright, MarkCollis, AlanFeng, ShuluGhanakota, PhaniHarriman, Geraldine C. C.Hosagrahara, VinayakKaila, NeeluKapeller, RosannaRafi, Salma B. B.Romero, Donna L. L.Tarantino, Paul M. M.Timaniya, JigneshToms, Angela V. V.Wester, Ronald T. T.Westlin, WilliamSrivastava, BhaskarMiao, WenyanTummino, PeterMcElwee, Joshua J. J.Edmondson, Scott D. D.Masse, Craig E. E.
- [3] Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasisJOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S46 - S46Krueger, J. G.Garcet, S.Cheng, J.Kumar, S.Tang, J.Blau, J.Zhao, Y.Zhang, W.Saha, B.Arunachalam, V.Heap, G. A.Thakker, P.Choudhury, A.
- [4] INFLUENCE OF PATIENT BASELINE CHARACTERISTICS ON TAK-279 EFFICACY, A SELECTIVE ORAL TYK2 INHIBITOR: PHASE 2B TRIAL IN PSORIATIC ARTHRITISACTA DERMATO-VENEREOLOGICA, 2024, 104Eder, LihiMuensterman, Elena Tomasellivan de Heijde, DesireeKivitz, AlanTrivedi, MonaHong, TingRehman, MuhammadWeng, Haoling HollyChen, JinglingBaraliakos, Xenofon
- [5] EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITISACTA DERMATO-VENEREOLOGICA, 2024, 104Kivitz, AlanMuensterman, Elena TomaselliKavanaugh, Arthurvan der Heijde, DesireeKlimiuk, Piotr A.Valenzuela, GuillermoDokoupilova, EvaPoirier, GabrielleSrivastava, BhaskarDasen, SueZhang, XinyanTrivedi, MonaWeng, Haoling HollyHong, TingPothula, PeterBaraliakos, Xenofon
- [6] A Novel, Oral, Allosteric Inhibitor of Tyrosine Kinase 2 (TYK2) Demonstrates In Vitro Potency, Selectivity, and In Vivo Efficacy in Mouse Models of PsoriasisARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1848 - 1849Hussein, RazikaTsuruda, PamelaMortezaei, ShahabFerdyan, NickyWegerski, ChristopherSrinivasan, KarthikHirst, GavinMozaffarian, Neelufar
- [7] Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic ArthritisARTHRITIS & RHEUMATOLOGY, 2023, 75 : 5216 - 5219Kivitz, AlanMuensterman, Elena TomaselliKavanaugh, Arthurvan der Heijde, DesireeKlimiuk, Piotr A.Valenzuela, GuillermoDokoupilova, EvaPoirier, GabrielleSrivastava, BhaskarDasen, SueZhang, XinyanTrivedi, MonaWeng, Haoling HollyHong, TingPothula, PeterBaraliakos, Xenofon
- [8] TAK-279, A SELECTIVE ORAL TYK2 INHIBITOR, REDUCES BSA INVOLVEMENT IN A PHASE 2B TRIAL IN MODERATE-TO-SEVERE PLAQUE PSORIASISACTA DERMATO-VENEREOLOGICA, 2024, 104Laquer, VivianKircik, LeonSadick, NeilWeisman, JamieZhao, Yi- weiBlau, JessamynZhang, WenwenUy, JonathanWinkelman, WarrenGooderham, Melinda
- [9] ABSOLUTE PASI REDUCTIONS IN A PHASE 2B TRIAL OF THE SELECTIVE ORAL TYK2 INHIBITOR, TAK-279, IN MODERATE-TO-SEVERE PLAQUE PSORIASISACTA DERMATO-VENEREOLOGICA, 2024, 104Green, LawrenceFerris, LauraMoore, AngelaZirwas, MatthewZhao, YiweiBlau, JessamynZhang, WenwenUy, JonathanWinkelman, WarrenVender, Ronald
- [10] Zasocitinib (TAK-279) Displays High Levels of TYK2 Inhibition and No Inhibition of JAK 1/3 Compared with Licensed TYK2 and JAK InhibitorsARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1845 - 1847Mehrotra, ShaillySano, YasuyoWilson, ElizabethDurairaj, ChandrasekarKong, Kok-FaiXia, GuliangDunbar, FaithSpector, TaylorBunick, ChristopherMcInnes, Iain